Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes
Multiple Myeloma and Plasma Cell Neoplasm
Northwestern UniversityCell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
498 Active assets in the Multiple Myeloma and Plasma Cell Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Jonsson Comprehensive Cancer Center | Phase 4 | BBB |
Inno-206 University of Arkansas | Phase 3 | BBB |
Hyaluronidase fihj Massachusetts General Hospital | Phase 4 | BBB |
Busulphan M.D. Anderson Cancer Center | Phase 4 | BBB |
Filanesib PETHEMA Foundation | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes is also rated in:
Epstein-Barr virus-associated lymphoproliferative disorderDormant
CC
Indicative ·
43 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →